{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"199.500","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2024","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"1,540,975,898","primaryexch":"HKEX","ric":"6160.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"B","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BVDKGC7","am":"1.62","iv":"","ew_strike":"","as":"196.200","geographic_focus":null,"incorpin":"Switzerland","etp_baseCur":null,"ew_amt_os":"","bd":"196.000","registrar":"Computershare Hong Kong Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-09-26 10:38:37.0","lo52":"103.100","shares_issued_date":"11 Sep 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"John V. Oyler","underlying_ric":"6160.HK","hi52":"213.000","issuer_name":"BeiGene, Ltd.","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 16:08","aum_date":"","lo":"190.000","mkt_cap":"302.33","f_aum_hkd":null,"ew_sub_per_to":"","ls":"196.200","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"-3.700","aum":"","issued_shares_class_B":null,"vo":"8.35","secondary_listing_flag":false,"listing_date":"8 Aug 2018","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"BeiGene, Ltd.","nm_s":"BEIGENE","sym":"6160","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.100","strike_price":"","summary":"BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.","op":"192.900","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"Rm 1901, 19/F, Lee Garden One<br/>33 Hysan Avenue<br/>Causeway Bay<br/>Hong Kong","pc":"-1.85","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"USD","hdr":false,"launch_date":"","hc":"199.900","isin":"CH1391448177","moneyness":""}},"qid":"1758889965994"}
